EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors

Tomohiro Kondo iD, Osamu Kikuchi, Yoshihiro Yamamoto, Tomohiko Sunami, Yafeng Wang, Keita Fukuyama, Tomoki Saito, Hideto Nakahara, Sachiko Minamiguchi, Masashi Kanai, Atsushi Sueyoshi, Manabu Muto iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae113 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, 2025. Verfasst von Tomohiro Kondo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare, recurrent oncogenic variant that constitutively activates EGFR in non-small-cell lung cancer. Herein, we report the case of a 70-year-old man with resectable colorectal adenocarcinoma who underwent surgery followed by adjuvant therapy. He relapsed with multiple liver metastases and received standard chemotherapy until his disease became refractory. Comprehensive genomic profiling of his postoperative colorectal cancer tissue revealed EGFR-KDD. He was treated with an EGFR tyrosine kinase inhibitor (TKI), afatinib and achieved a partial response (− 55%) after 8 weeks; however, he developed massive malignant ascites after 13 weeks. Osimertinib, another EGFR-TKI, controlled his tumors for 9 months. Patient-derived cancer organoids from his malignant ascites confirmed sensitivity to EGFR-TKIs. The findings suggest that EGFR-TKIs can be a potential treatment option for this molecular subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsColorectal NeoplasmsHumansMaleAgedErbB ReceptorsAcrylamidesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

afatinibcomprehensive genomic profilingepidermal growth factor receptor (EGFR)kinase domain duplicationosimertinib

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAcrylamidesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Japan Society for the Promotion of Science, Tokyo, Japan.
  • Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan.
  • Department of Surgery, Uji Tokushukai Medical Center, Uji, Japan.
  • Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
  • Uji-Tokushukai Medical Center, Uji, Japan.

ORCID-Profile: Tomohiro Kondo, Manabu Muto

Zitieren

APA

Kondo, T., Kikuchi, O., Yamamoto, Y., Sunami, T., Wang, Y., Fukuyama, K., Saito, T., Nakahara, H., Minamiguchi, S., Kanai, M., Sueyoshi, A., & Muto, M. (2025). Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyae113

Vancouver

Kondo T, Kikuchi O, Yamamoto Y, Sunami T, Wang Y, Fukuyama K, et al. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors. The Oncologist. 2025. doi:10.1093/oncolo/oyae113

BibTeX
@article{Kondo2025,
  author = {Kondo, Tomohiro and Kikuchi, Osamu and Yamamoto, Yoshihiro and Sunami, Tomohiko and Wang, Yafeng and Fukuyama, Keita and Saito, Tomoki and Nakahara, Hideto and Minamiguchi, Sachiko and Kanai, Masashi and Sueyoshi, Atsushi and Muto, Manabu},
  title = {Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae113}
}
Kostenlos starten →